526 related articles for article (PubMed ID: 25733633)
21. Environmental factors in multiple sclerosis.
Pantazou V; Schluep M; Du Pasquier R
Presse Med; 2015 Apr; 44(4 Pt 2):e113-20. PubMed ID: 25744944
[TBL] [Abstract][Full Text] [Related]
22. Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial.
Dower JI; Geleijnse JM; Gijsbers L; Zock PL; Kromhout D; Hollman PC
Am J Clin Nutr; 2015 May; 101(5):914-21. PubMed ID: 25934864
[TBL] [Abstract][Full Text] [Related]
23. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
Dubey D; Kieseier BC; Hartung HP; Hemmer B; Warnke C; Menge T; Miller-Little WA; Stuve O
Expert Rev Neurother; 2015 Apr; 15(4):339-46. PubMed ID: 25800129
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.
Åivo J; Hänninen A; Ilonen J; Soilu-Hänninen M
J Neuroimmunol; 2015 Mar; 280():12-5. PubMed ID: 25773149
[TBL] [Abstract][Full Text] [Related]
25. Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation.
Offermanns S; Schwaninger M
Trends Mol Med; 2015 Apr; 21(4):245-55. PubMed ID: 25766751
[TBL] [Abstract][Full Text] [Related]
26. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
27. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
D'Amico E; Messina S; Caserta C; Patti F
Expert Opin Drug Saf; 2015 Jul; 14(7):1157-68. PubMed ID: 25826609
[TBL] [Abstract][Full Text] [Related]
28. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
30. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.
Amato MP; Portaccio E
CNS Drugs; 2015 Mar; 29(3):207-20. PubMed ID: 25773609
[TBL] [Abstract][Full Text] [Related]
31. Long-term green tea extract supplementation does not affect fat absorption, resting energy expenditure, and body composition in adults.
Janssens PL; Hursel R; Westerterp-Plantenga MS
J Nutr; 2015 May; 145(5):864-70. PubMed ID: 25740906
[TBL] [Abstract][Full Text] [Related]
32. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
33. Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.
Rinaldi F; Perini P; Atzori M; Favaretto A; Seppi D; Gallo P
Mult Scler Int; 2015; 2015():369348. PubMed ID: 25802758
[TBL] [Abstract][Full Text] [Related]
34. Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS.
Streeter HB; Rigden R; Martin KF; Scolding NJ; Wraith DC
Neurol Neuroimmunol Neuroinflamm; 2015 Jun; 2(3):e93. PubMed ID: 25798453
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Røsjø E; Myhr KM; Løken-Amsrud KI; Bakke SJ; Beiske AG; Bjerve KS; Hovdal H; Lilleås F; Midgard R; Pedersen T; Šaltytė Benth J; Torkildsen Ø; Wergeland S; Michelsen AE; Aukrust P; Ueland T; Holmøy T
J Neuroimmunol; 2015 Mar; 280():21-8. PubMed ID: 25773151
[TBL] [Abstract][Full Text] [Related]
36. Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.
Mattoscio M; Nicholas R; Sormani MP; Malik O; Lee JS; Waldman AD; Dazzi F; Muraro PA
Neurology; 2015 Apr; 84(14):1473-82. PubMed ID: 25762712
[TBL] [Abstract][Full Text] [Related]
37. Visual pathway neurodegeneration winged by mitochondrial dysfunction.
Petzold A; Nijland PG; Balk LJ; Amorini AM; Lazzarino G; Wattjes MP; Gasperini C; van der Valk P; Tavazzi B; Lazzarino G; van Horssen J
Ann Clin Transl Neurol; 2015 Feb; 2(2):140-50. PubMed ID: 25750919
[TBL] [Abstract][Full Text] [Related]
38. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.
Spencer CM; Crabtree-Hartman EC; Lehmann-Horn K; Cree BA; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2015 Jun; 2(3):e76. PubMed ID: 25738172
[TBL] [Abstract][Full Text] [Related]
39. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial.
Mastroiacovo D; Kwik-Uribe C; Grassi D; Necozione S; Raffaele A; Pistacchio L; Righetti R; Bocale R; Lechiara MC; Marini C; Ferri C; Desideri G
Am J Clin Nutr; 2015 Mar; 101(3):538-48. PubMed ID: 25733639
[TBL] [Abstract][Full Text] [Related]
40. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.
von Büdingen HC; Palanichamy A; Lehmann-Horn K; Michel BA; Zamvil SS
Eur Neurol; 2015; 73(3-4):238-246. PubMed ID: 25824054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
